

# Novel Role of Transmembrane SCF for Mast Cell Activation and Eotaxin Production in Mast Cell-Fibroblast Interactions<sup>1</sup>

Cory Hogaboam,\* Steven L. Kunkel,\* Robert M. Strieter,<sup>†</sup> Dennis D. Taub,<sup>‡</sup> Pam Lincoln,\* Theodore J. Standiford,<sup>†</sup> and Nicholas W. Lukacs<sup>2\*</sup>

Mast cell activation can be induced by multiple mechanisms, including IgE-, complement-, and stem cell factor (SCF)-mediated pathways. In addition, the interaction of mast cells with particular cell populations, such as fibroblasts, have also demonstrated increased mast cell reactivity. In these studies, we have investigated the role of fibroblast-mast cell interaction for induction of histamine release and chemokine production and the specific role of SCF during this interaction. Primary pulmonary fibroblast cell lines were grown in culture and used throughout these studies. Mast cells were grown in parallel with fibroblasts by incubation of bone marrow cells with SCF and IL-3. During mast cell-fibroblast coculture, increased histamine release could be attenuated either by separation of the cell populations using a Trans-Well setup, which did not allow cellular contact, or by specific anti-SCF Ab. In addition, a significant increase in eotaxin, a potent eosinophil-specific C-C chemokine, was also observed during fibroblast-mast cell interaction. The production of eotaxin was cell contact dependent and could be inhibited using an anti-SCF Ab or specific antisense therapy. SCF was constitutively produced from fibroblasts in its transmembrane form and could be induced by TNF. SCF-coated plates induced significant mast cell-derived eotaxin production, whereas soluble SCF induced little or no eotaxin, suggesting a necessity for receptor cross-linking for activation. These studies indicate that fibroblast-mast cell contact plays a role in exacerbation of histamine release and eotaxin production. *The Journal of Immunology*, 1998, 160: 6166–6171.

The role of mast cells in chronic inflammatory responses has been controversial in recent years. Although it appears that significant numbers of mast cells are present during these processes, a true causal relationship has not been established (1–3). The results from mast cell-deficient mice have demonstrated that disease processes may progress normally without mast cells. In particular, bleomycin-induced lung fibrosis results have demonstrated that the pathologic events appear to be similar in mast cell-deficient and littermate control mice (4). However, during disease development in normal mice, a significant increase in mast cells is observed (5). Studies using mast cell-deficient mice in allergic airway inflammation has demonstrated results that suggest that mast cells are involved in allergic airway inflammation, and human studies indicate that there are increased numbers of mast cells in asthmatics (6, 7). It is clear that mast cells can participate in several aspects of disease progression, including immediate hyperreactive responses, production of acute mediators, cytokines, angiogenic and fibrotic factors, and release of chemokines that may exacerbate these responses (8–15). Interestingly, in most diseases that have significant mast cell activation, there appears to be an associative increase in eosinophils, including allergic (asthmatic) and fibrotic responses. This relationship between

mast cell activation and eosinophil accumulation likely has substantial consequences on disease pathology.

The interaction of mast cells with surrounding cell populations during inflammatory events may be critical for the progression of these responses. For example, in chronic fibrotic lesions, a correlation exists between the number of mast cells and the severity of fibrosis (16, 17). Since mast cells depend upon stem cell factor (SCF)<sup>3</sup> to avoid apoptosis (18), the production of SCF by surrounding cell populations is critical. Adding to the complexity of mast cell requirements for SCF is the fact that SCF can be found in either a soluble or transmembrane form and may differentially contribute to mast cell activation (19). In addition, SCF has also been shown to mediate mast cell adherence events that allow mast cells to bind to other structural cell populations (20, 21), which is important to their survival and activation (22–25). Furthermore, data have shown that incubation of mast cells with fibroblasts can induce proliferation and differentiation of mast cells (26). Finally, recent data have indicated that mast cell interaction with fibroblasts can induce collagen gene activation (27, 28) and, therefore, contribute to fibrosis during disease progression.

Few studies have examined either the mechanisms that are operative during the cellular interactions or the cytokines that are produced during fibroblast-mast cell interactions. In particular, chemokines that are produced during chronic inflammation may be critical to the progression of the pathologic responses. Interestingly, the eosinophil has been identified as a potential effector cell in both chronic allergic responses and fibrotic diseases. The identification of C-C family chemokines that are produced during the cell-to-cell interaction may be pertinent to the overall inflammatory response. Eotaxin, which appears to specifically recruit eosinophils, may play a primary role in these chronic diseases (29, 30). Since both mast cells and fibroblasts are able to produce chemokines, the cell-to-cell interaction may promote considerable

Departments of \*Pathology and <sup>†</sup>Internal Medicine, Division of Pulmonary and Critical Care, University of Michigan Medical School, Ann Arbor, MI 48109; and <sup>‡</sup>National Cancer Institute, Frederick, MD 21702

Received for publication August 27, 1997. Accepted for publication February 17, 1998.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This work was supported in part by National Institutes of Health Grants AI36302, HL59178, and The American Lung Association.

<sup>2</sup> Address correspondence and reprint requests to Dr. Nicholas W. Lukacs, Ph.D., Department of Pathology, University of Michigan Medical School, 1301 Catherine, Ann Arbor, MI 48109-0602.

<sup>3</sup> Abbreviations used in this paper: SCF, stem cell factor.

production and therefore cause increased leukocyte accumulation at the site of the response. In the present studies, we have used fibroblast-mast cell cocultures to examine the role and production of histamine and eotaxin from the two cell populations. Interestingly, eotaxin was specifically up-regulated during the cocultures by transmembrane SCF, possibly indicating a specific activation role during disease, which relates to eosinophil accumulation.

## Materials and Methods

### Isolation and expansion of mast cells

Mast cell lines were derived from the bone marrow of pathogen-free CBA/J mice (The Jackson Laboratory, Bar Harbor, ME), which was perfused from femurs (31). The cells were incubated with Dulbecco's MEM supplemented with 1 mM L-glutamine, 10 mM HEPES, antibiotics, and 10% FCS with IL-3 (10 ng/ml) and SCF (10 ng/ml). By the end of 2–3 wk, a nonadherent population of large granular cells was observed. These isolated cells appeared homogeneous in cytospin preparations stained by Diff Quik (Baxter Diagnostics, McGaw Park, IL) with a typical mast cell granular appearance. The homogeneity of these cell lines was determined by flow cytometric analysis of surface markers, by histamine release assays (IgE + Ag), and by electron microscopy. In particular, these cells were *c-kit* positive (SCF receptor) but were negative for CD3, CD4, CD8, CD23, B220, and F480 by flow cytometry. These cell lines were routinely expanded, as described above, for 4 to 6 wk.

### Pulmonary-derived fibroblasts

Whole mouse lungs were excised from a normal CBA/J mouse, cut in 1-mm sections, and washed twice with PBS (pH 7.2). The lung pieces were incubated in 75-mm<sup>2</sup> flasks in DMEM supplemented with 1 mM L-glutamine, 10 mM HEPES, antibiotics, and 10% FCS. After fibroblasts began growing out from the primary lung explants, the tissue pieces were removed. The fibroblasts were allowed to grow until near confluency and were then trypsinized (0.25%) off the flask and transferred to a 2 × 150-mm<sup>2</sup> culture flask. This was repeated once more before plating the fibroblast cells into 35-mm plates. Fibroblasts were allowed to grow in the culture dishes until they were near confluency. The expansion process required ~28 days, and <1% of passenger cells (i.e., macrophages) were observed by nonspecific esterase stain.

### Fibroblast-mast cell cocultures

Cultured mast cell populations ( $2 \times 10^5$ ) were added to six-well plates with or without confluent primary fibroblast cultures. After 24 h, the culture supernatants were harvested and frozen at -20°C. In some cultures, the cell populations were separated by a 0.45- $\mu$ m membrane in a Trans-Well culture dish (Costar, Kennebunkport, ME) or cocultured with anti-SCF serum (1:100 dilution). In some experiments, fibroblasts were preincubated with TNF for 6 to 8 h before mast cell coculture.

### Production of anti-SCF and anti-eotaxin Abs

Rabbit anti-murine SCF and anti-eotaxin Abs were prepared by multiple-site immunization of New Zealand White rabbits with recombinant murine SCF or eotaxin (Genzyme, Cambridge, MA) in CFA. Polyclonal Abs were titrated by direct ELISA and specifically verified by the failure to cross-react to mIL-3, mIL-1 $\alpha$ , mTNF, mMIP-1 $\alpha$ , IL-6, mJE, mMIP-1 $\beta$ , hMCP-1, hIL-8, hRANTES, hMIP-1 $\alpha$ , hTNF, and hMIP-1 $\beta$ . The IgG portion of the serum was purified over a protein A column and used in a sandwich ELISA.

### ELISAs

Mouse-specific cytokines were quantitated by ELISA using a modification of a double-ligand method as previously described (32). Briefly, flat-bottom 96-well microtiter plates (Immuno-Plate I 96-F; Nunc, Roskilde, Denmark) were coated with 50  $\mu$ l/well of rabbit anti-SCF or anti-eotaxin Ab (in 0.6 M NaCl, 0.26 M H<sub>3</sub>BO<sub>3</sub>, and 0.08 N NaOH, pH 9.6) for 16 h at 4°C and then washed with PBS, pH 7.5, and 0.05% Tween-20 (wash buffer). Nonspecific binding sites were blocked with 2% BSA in PBS and incubated for 90 min at 37°C. Standards were 1/2-log dilutions of recombinant cytokines from 10 pg/ml to 100 ng/ml. This ELISA method consistently detected cytokine concentrations above 50 pg/ml. The specific Ab ELISAs did not cross-react with each other or with other cytokines or chemokines, including mIL-3, mIL-1 $\alpha$ , mTNF, mMIP-1 $\alpha$ , IL-6, mJE, mMIP-1 $\beta$ , hMCP-1, hIL-8, hRANTES, hMIP-1 $\alpha$ , hTNF, and hMIP-1 $\beta$ .

### Histamine release assays

Histamine levels in supernatants were determined by ELISA (Amac, Westbrook, ME). As positive controls, mast cells were exposed to compound 48/80 (Sigma) and a mast cell degranulator, and cells were sonicated to determine total intracellular histamine levels.

### Measurement of SCF from pulmonary fibroblasts

Confluent 35-mm plate cultures were coincubated with various cytokines (IL-1, TNF, IL-4, IFN- $\gamma$ , and IL-10) at various concentrations (0.1, 1.0, and 10 ng/ml). After 24 h, supernatants were harvested, and the adherent fibroblast cells were lifted off the plates using Ca<sup>2+</sup>- and Mg<sup>2+</sup>-free HBSS at 4°C for 15 min. Once the fibroblasts were lifted from the culture dishes, the cells were lysed by sonication and the cytoplasmic and membrane portions of the cells were separated by ultracentrifugation (100,000 × g). After separation, the membrane fractions were lysed with PBS containing Triton X-100 (0.1%). The culture supernatant, cytoplasmic, and lysed membrane fractions were all assayed by specific SCF ELISA. No problem was encountered in the ELISA with the nonionic detergent Triton X-100.

### mRNA analysis and antisense therapy

Total cellular RNA from the cultures was isolated by homogenizing in a solution containing 25 mM Tris, pH 8.0, 4.2 M guanidine isothiocyanate, 0.5% Sarkosyl, and 0.1 M 2-ME. After homogenization, the suspension was added to a solution containing an equal volume of 100 mM Tris, pH 8.0, 10 mM EDTA, and 1.0% SDS. The mixture was then extracted two times each with phenol-chloroform and chloroform-isoamyl alcohol. The RNA was alcohol precipitated, and the pellet was dissolved in diethyl pyrocarbonate water. Total RNA was determined by spectrometric analysis at a 260-nm wavelength. Five  $\mu$ g of total RNA was reverse transcribed into cDNA utilizing a BRL reverse transcription kit (BRL, Gaithersburg, MD) and oligo(dT)<sub>12-18</sub> primers. The cDNA was then amplified using specific primers for  $\beta$ -actin, soluble SCF, and a transmembrane form of SCF. The primers used were 5'-GTG GGG CGC CCC AGG CAC CA-3' (sense) and 5'-GCT CGC CCG TGG TGG TGA AGC-3' (antisense) for  $\beta$ -actin (350 bp), 5'-CAC TCA GCT TGA CTA CTC TT-3' (sense) and 5'-GTC ATT CCT AAG GGA GCT GG-3' (antisense) for soluble SCF (358 bp), and 5'-CAC TCA GCT TGA CTA CTC TT-3' (sense) and 5'-TTG CGG CTT TCC CTT TCT CG-3' (antisense) for transmembrane SCF (302 bp). The amplification buffer contained 50 mM KCl, 10 mM Tris-HCl (pH 8.3), and 2.5 mM MgCl. Specific oligonucleotide primer was added (200 ng/sample) to the buffer, along with 1  $\mu$ l of the reverse-transcribed cDNA samples. The cDNA was amplified after determining the optimal number of cycles. The mixture was first incubated for 5 min at 94°C and then was cycled 30 times at 95°C for 30 s, followed by 58°C for 45 s, and elongated at 72°C for 75 s. This format allowed optimal amplification with little or no nonspecific amplification of contaminating DNA. After amplification, the sample (20  $\mu$ l) was separated on a 2% agarose gel containing 0.3  $\mu$ g/ml (0.003%) of ethidium bromide. The bands were visualized and photographed using UV transillumination.

Phosphorothioate-linked antisense and sense SCF oligonucleotides were used at 20  $\mu$ M in tissue culture by preincubating the fibroblasts overnight before and during mast cell coculture. This level was shown to significantly inhibit the level of SCF protein produced by the lung fibroblasts in preliminary experiments with the antisense but not with the sense oligonucleotide. Sequences were 5'-CTGATCGCAGCGCTGCCTTTCCT TATGA-3' for the sense and 5'-TCATAAGGAAAGGCAGCGCTGC GATCCAG-3' for the antisense oligonucleotide.


### Statistics

Statistical significance was determined by ANOVA, and significance was determined with *p* values <0.05.

## Results

### Fibroblast-mast cell cocultures induce histamine release and eotaxin production

Stromal cells and mast cells are in intimate contact within tissues where mast cells reside. During chronic disease pathology, such as in fibrosis and allergic diseases, the numbers of both mast cells and stromal cells increase. Previous studies have demonstrated a significant role for fibroblasts in mast cell differentiation, activation, and proliferation (22–25, 33). Figure 1 demonstrates that during fibroblast-mast cell interaction, a substantial activation event occurs as monitored by histamine release from 24-h cocultures. The




**FIGURE 1.** Induction of histamine release during fibroblast-mast cell interaction is dependent on contact and SCF interaction. Mast cells ( $1 \times 10^5$ ) were layered onto monolayers of normal lung fibroblasts. Histamine levels were assayed in the 24-h cell-free supernatant. Data represent means  $\pm$  SE from three repeated experiments. \* signifies  $p < 0.05$ , and \*\* signifies  $p < 0.01$  compared with mast cells + fibroblasts.

degranulation appears to require cell-to-cell contact, as separation of the cell populations with a  $0.45 \mu\text{m}$  Trans-Well culture dish significantly decreased histamine release. Interestingly, there was still a significant histamine release in Trans-Well culture dishes when fibroblasts were present in the lower chamber. Finally, if fibroblasts were incubated with TNF 6 h before the addition of the mast cells and then washed, the histamine release response was significantly augmented. Preactivation of the fibroblasts with other cytokines, including IL-4, IL-1, and IFN- $\gamma$ , had no effect on histamine release (data not shown).

One of the most important events to occur during infectious diseases is the recruitment of leukocytes. When bone marrow mast cells were combined with the pulmonary fibroblasts, a significant increase in eotaxin, a C-C chemokine family member that can specifically recruit certain leukocyte populations, was observed. The fibroblast-mast cell interaction produced significant increases in levels of eotaxin (Fig. 2) when the cell populations were combined. Preactivation of the fibroblast populations with increasing levels of TNF induced significant increases in the release of eotaxin during cell-to-cell interactions (Fig. 2); however, TNF did not induce eotaxin production in either fibroblasts or mast cells alone (data not shown). Preactivation of the fibroblasts with other cytokines, such as IL-1 and IFN- $\gamma$ , had no effect on the eotaxin production (data not shown). Altogether, these studies verify earlier studies demonstrating that fibroblast-mast cell interaction leads to an activation/degranulation event.


#### *Histamine and eotaxin production is mediated by SCF during fibroblast-mast cell interaction*

Previous studies have indicated that fibroblast populations can augment mast cell activation and differentiation. Separation of the two cell populations by a Trans-Well membrane significantly attenuated the eotaxin production (Fig. 3), indicating that cell-to-cell interactions were required. These responses may be exaggerated by the production of a major mast cell growth and survival factor,




**FIGURE 2.** Induction of eotaxin during mast cell-fibroblast interaction can be augmented by preincubation of the fibroblasts with TNF- $\alpha$ . Mast cells ( $1 \times 10^5$ ) were layered onto monolayers of normal lung fibroblasts. Eotaxin levels were measured in 24-h cell-free supernatants using specific ELISAs. Fibroblasts were preincubated overnight with TNF (1.0 or 10 ng/ml) and washed before addition of mast cells. TNF does not up-regulate eotaxin from lung fibroblasts. Data are representative of three repeated experiments. \* signifies  $p < 0.05$ , and \*\* signifies  $p < 0.01$ .

SCF. Preactivation of the fibroblast with anti-SCF demonstrated that histamine release in 24-h-accumulation cultures could be attenuated (Fig. 1). Likewise, regulation of eotaxin production was



**FIGURE 3.** Eotaxin production is contact dependent and specifically inhibited by anti-SCF during fibroblast-mast cell interaction. Mast cells ( $1 \times 10^5$ ) were layered onto monolayers of normal lung fibroblasts. Polyclonal anti-SCF Ab (1:200 dilution) was added to the fibroblast cultures 30 min before the mast cells. Eotaxin was assayed in 24-h culture supernatants. Data represent means  $\pm$  SE from three different experiments. \* signifies  $p < 0.05$  compared with mast cells + fibroblasts + control Ab.

**FIGURE 4.** Antisense oligonucleotide specific for SCF blocks eotaxin production during fibroblast-mast cell interaction. Antisense SCF was incubated with fibroblasts 24 h before and during the coculture of mast cells at 20  $\mu$ M concentration. This concentration demonstrated a >75% reduction in SCF from fibroblasts in these studies. Eotaxin was measured in 24-h culture supernatants. Data represent means  $\pm$  SE of six repeats. \* signifies  $p < 0.05$  compared with mast cells + fibroblasts + sense SCF.



observed by the anti-SCF treatment during the cell-to-cell interaction (Fig. 3). In addition, we have also constructed sense and antisense oligonucleotides specific for SCF and inhibited the production of eotaxin by preincubation (overnight) of fibroblasts with the antisense, but not sense, SCF-specific nucleotides (Fig. 4). The use of the antisense SCF oligonucleotide demonstrated a significant reduction in isolated membrane SCF production by the fibroblasts compared with the sense-treated cells ( $0.48 \pm 0.24$  vs  $2.0 \pm 0.12$  ng/ml, respectively). To determine whether SCF on its own was enough to drive eotaxin production, we stimulated mast cells with soluble SCF or by SCF-coated plates to simulate the transmembrane form. The data in Table I indicate that eotaxin was produced only on SCF-coated plates and not by soluble SCF after 24 h of incubation. Interestingly, other degranulating stimuli, such as 48/80 and IgE + Ag, demonstrated no eotaxin production from the mast cells, while they did induce histamine release (15 and 12% of total, respectively) as previously described (34), further demonstrating the importance of SCF-mediated activation in eotaxin production. Interestingly, when soluble SCF was added into the mast cells plated onto the plate-bound cultures, an inhibition of eotaxin production was observed, suggesting a blockage of the cross-linking of *c-kit*. These data suggest that SCF can drive eotaxin production primarily in its solid phase form and that the different forms of SCF may have specific regulatory functions in chemokine production.


*SCF production from fibroblast is predominantly in the transmembrane form*

To better define the role of SCF during fibroblast-mast cell interaction, we have examined pulmonary fibroblasts stimulated with various inflammatory stimuli, including IL-1, IL-4, TNF, IFN- $\gamma$ ,

Table I. Solid phase, but not soluble, SCF induces eotaxin in mast cells

Group	Eotaxin
Mast cells	<50 pg/ml
Mast cells + SCF (10 ng/ml)	<50 pg/ml
Mast cells + SCF (50 ng/ml)	<50 pg/ml
Mast cells + SCF-coated plates	$5.75 \pm 2.7$ ng/ml
Mast cells + SCF-coated plates + soluble SCF (10 ng/ml)	<50 pg/ml
Mast cells + IgE + Ag	<50 pg/ml
Mast cells + 48/80	<50 pg/ml

and IL-10. After 24 h poststimulation, cell-free culture supernatants were harvested. Sonicated fibroblasts were separated by ultracentrifugation to separate membrane from soluble components. The membrane portion was dispersed with PBS containing 0.1% Triton X-100. Little or no SCF protein was measured in the supernatant fraction of the stimulated fibroblasts (<100 pg/ml). However, nearly all of the detectable SCF was in the membrane fractions of the stimulated fibroblasts. Interestingly, substantial levels of SCF were detected in control fibroblasts (2.0–2.5 ng/ml), while only TNF-stimulated fibroblasts produced increases in membrane SCF (Fig. 5). All of the SCF protein from the sonicated fibroblasts was detected in the membrane fraction, and none was found in the cytoplasmic portion. These data help to explain why cell-to-cell interactions were required above for the SCF-mediated



**FIGURE 5.** Transmembrane SCF is up-regulated by TNF- $\alpha$  in pulmonary fibroblasts. Confluent pulmonary fibroblasts were incubated (24 h) with various cytokines (10 ng/ml), and both the culture supernatant and isolated Triton X-100 membrane lysates (see *Materials and Methods*) were assayed for SCF using a specific ELISA. No SCF has been detected in the culture supernatants from the stimulated pulmonary fibroblasts. Data are from a representative experiment that has been repeated several times with similar results. \* signifies  $p < 0.05$ .



mast cell activation, histamine release, and eotaxin production. To verify this aspect, the lung fibroblasts were assayed for SCF-specific mRNA using specific primers that differentially recognize soluble or transmembrane forms of SCF. Both forms of SCF were detectable by reverse transcription-PCR techniques (data not shown). Altogether, it appears that the mast cell activation described above is driven, at least in part, by the transmembrane form of SCF that is found constitutively and can be up-regulated by TNF in normal lung fibroblasts.

## Discussion

The persistent activation of mast cells during chronic inflammation may contribute to the pathogenesis of a number of chronic inflammatory disorders. Mast cells participate in several biologic processes, including acute inflammatory and allergic responses, angiogenesis, fibrosis, and leukocyte recruitment. The latter process appears to be one of the most critical events that occurs during acute and chronic inflammation. The persistent influx and activation of particular leukocyte populations is thought to promote and maintain chronic allergic and fibrotic disease phenotypes. In the present study, we have examined one possible mechanism of persistent eosinophil recruitment through the production of eotaxin during mast cell-fibroblast interactions. Both of these cell populations have the ability to produce significant levels of eotaxin. However, the fact that these cells may work together to produce synergistic levels of eotaxin during cell-to-cell interaction may help to explain their relationship during disease progression. In addition to the observations that eotaxin and histamine are released during the interaction of the two cell populations, it appears that transmembrane SCF is, in part, responsible for their interaction. This latter observation is supported by earlier investigations that identified SCF as a mediator of mast cell binding to cells and matrix (20, 21). The fact that fibroblast-derived SCF is transmembrane may relate to the close proximity of the two cell populations in tissue and may further suggest an intimate/necessary relationship for mast cell survival. Since SCF is required for long-term mast cell survival (18), the stromal cell populations that surround tissue mast cells may provide a "steady-state" level of transmembrane SCF, which maintains mast cell survival. However, during disease states, when cytokine cascades (TNF) are initiated, the increased expression of SCF (as well as other adhesive interactions) may trigger the mast cell and heighten its activational state. This idea may be indicative of chronic fibrotic diseases in which an increased number of mast cells can be observed within fibrotic lesions (5, 16, 17). Interestingly, we have described a role for SCF in allergic airway disease, in which SCF overproduction appears to augment the response of mast cells and allow persistent and prolonged activation leading to eosinophil accumulation into the airways (36). Eotaxin production, an eosinophil-specific chemotactic factor, was dependent upon SCF during the fibroblast-mast cell interaction in the present studies. Although both cell populations have the ability to produce eotaxin, these studies demonstrate that mast cells can be induced to produce eotaxin by transmembrane SCF. However, previous studies have shown that fibroblasts can also be induced to produce eotaxin only by IL-4 stimulation (our unpublished data). It is conceivable that SCF is activating the mast cell to release products, including IL-4, which conversely activate the fibroblast to increase its production of eotaxin (our studies in progress). Overall, however, these data suggest a regulatory role for SCF in mast cell activation and eotaxin production.

The fact that fibroblast cell populations can produce a distinct form of SCF may indicate a divergence in the function of soluble vs transmembrane SCF. In the present studies, plate-

bound, but not soluble, SCF drove eotaxin production. The production of membrane SCF from stromal cell populations may contribute to the normal maintenance and/or to the normal healing process within tissue. The overzealous production of transmembrane SCF may lead to augmented and persistent mast cell activation, eotaxin production, eosinophil recruitment, and tissue pathology. SCF activates mast cells via *c-kit*, a protein tyrosine kinase-coupled receptor. It appears from the present studies that eotaxin production is dependent upon cross-linking of these receptors in a solid phase. These events would be indicative of the overproduction of eotaxin, leukocyte recruitment and activation, and, finally, tissue pathology. Although there is a paucity of data to support these concepts, the idea of SCF in chronic disease progression has been demonstrated in other investigations. SCF has been linked to eosinophil accumulation not only in allergic models of inflammation (36) but also in infectious parasitic models in which the neutralization of SCF decreased the accumulation of eosinophils, the effector cells in many parasitic infections (37). Thus, although SCF may play a detrimental effect in chronic inflammatory diseases such as asthma, it may be beneficial in infectious parasitic diseases.

The relationship between mast cell activation and eosinophilia repeats itself throughout various types of chronic inflammatory events. In allergic inflammation, the persistent activation of mast cells appears to be a primary event that may directly lead to the accumulation of eosinophils (38). This would be mediated by the level and the type of chemokines that are produced during the mast cell activation. In the most severe cases of allergic asthma, a considerable level of stromal cell proliferation and "airway thickening" is observed within the large airways, where mast cells are predominantly found. The interrelationship between mast cells, transmigrating eosinophils, and the increased numbers of activated stromal cells may contribute to the chronicity and severity of the asthmatic responses. In chronic fibrotic diseases, it has now been reported that a significant influx of eosinophils may participate in the maintenance of the fibrotic response (39, 40). Interestingly, there may be a strong relationship between the severity of the fibrotic event and the number of mast cells and eosinophils that are present. This would be exemplified in these studies by the SCF-dependent expression of eotaxin, a C-C chemokine with potent eosinophil chemoattractant and activating functions (41–43). The persistent activation of mast cells and eotaxin production within these disease states may relate to the constant influx of leukocytes (eosinophils) that appear to mediate the tissue pathology even in the cases in which an Ag stimulus may not be apparent. Although previous studies have not observed eotaxin production from mast cells (44, 45), the transmembrane SCF-induced mechanism was not examined. In addition, there may be an effect due to the maturity of the mast cell population, as studies have shown that a heterogeneous population of mast cells likely exists within any culture of mast cells grown from bone marrow cells (46).

The results from these studies have outlined a novel relationship between mast cell and fibroblast populations. The production of histamine and chemokines during this interaction indicates a possible mechanism for disease progression. Transmembrane SCF may have a role in exacerbation of mast cell activation (histamine release) and eotaxin production, which could subsequently lead to increased eosinophil accumulation and tissue pathology. Future studies will examine the expression of SCF in fibroblast populations from inflammatory and fibrotic lesions, as up-regulated production of SCF may exacerbate and maintain the altered disease status.

## References

1. Wasserman, S. I. 1989. Mast cell-mediated inflammation in asthma. *Ann. Allergy* 63:546.
2. Holgate, S. T. 1988. *Mast Cells, Mediators and Disease*. Klug Academic Publishers, London.
3. Jordana, M. 1993. Mast cells and fibrosis: who's on first? *Am J. Respir. Cell Mol. Biol.* 8:7.
4. Mori, H., K. Kawada, P. Zhang, Y. Uesugi, O. Sakamoto, and A. Koda. 1991. Bleomycin-induced pulmonary fibrosis in genetically mast cell deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of transilast, an antiallergic drug inhibiting mediator release from mast cell, on fibrosis. *Int. Arch. Allergy Appl. Immunol.* 95:195.
5. Goto, T., D. Befus, R. Low, and J. Bienenstock. 1984. Mast cell heterogeneity and hyperplasia in bleomycin-induced pulmonary fibrosis of rats. *Am. Rev. Respir. Dis.* 130:797.
6. Crimi, E., M. Chiaramonda, M. Milanese, G. A. Rossi, and V. Brusasco. 1991. Increased numbers of mast cells in bronchial mucosa after the late-phase asthmatic response to allergen. *Am. Rev. Respir. Dis.* 144:1282.
7. Kung, T. T., D. Stelts, J. A. Zurcher, H. Jones, S. P. Umland, W. Kreutner, R. W. Egan, and R. W. Chapman. 1995. Mast cells modulate allergic pulmonary eosinophilia in mice. *Am. J. Respir. Cell Mol. Biol.* 12:404.
8. Undem, B. J., L. M. Lichtenstein, W. C. Hubbard, S. Meeker, and J. L. Ellis. 1994. Recombinant stem cell factor-induced mast cell activation and smooth muscle contraction in human blood. *Am. J. Respir. Cell Mol. Biol.* 11:646.
9. Selvan, R. S., J. H. Butterfield, and M. S. Krangel. 1994. Expression of multiple chemokine genes by a human mast cell leukemia. *J. Biol. Chem.* 269:13893.
10. Wilson S. D., V. K. Kuchroo, D. I. Israel, and M. E. Dorf. 1990. Expression and characterization of TCA3: a murine inflammatory protein. *J. Immunol.* 145:2745.
11. Russi, E. W., A. P. Perruchoud, L. D. Yerger, J. S. Stevenson, J. Tabak, B. Marchette, and W. M. Abraham. 1984. Late phase bronchial obstruction following nonimmunologic mast cell degranulation. *J. Appl. Physiol.* 57:1182.
12. Meininger, C. J., and B. R. Zetter. 1992. Mast cells and angiogenesis. *Semin. Cancer Biol.* 3:73.
13. Galli, S. J., J. R. Gordon, and B. K. Worthall. 1991. Cytokine production by mast cells and basophils. *Curr. Opin. Immunol.* 3:865.
14. Kulmburg, P. A., N. E. Huber, B. J. Scheer, M. Wrann, and T. Baumruker. 1992. Immunoglobulin E plus antigen challenge induces a novel intercrine/chemokine in mouse mast cells. *J. Exp. Med.* 176:1773.
15. Broide, D. H., C. M. Smith, and S. I. Wasserman. 1990. Mast cells and pulmonary fibrosis: identification of a histamine releasing factor in bronchoalveolar lavage fluid. *J. Immunol.* 145:1838.
16. Hawkins, R. A., H. N. Claman, R. A. Clark, and J. C. Steigerwald. 1985. Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? *Ann. Intern. Med.* 102:182.
17. Keith I., R. Day, S. Lemaire, and I. Lemaire. 1987. Asbestos-induced fibrosis in rats: increase in lung mast cells and autacid contents. *Exp. Lung Res.* 13:311.
18. Iemura, A., M. Tsai, A. Ando, B. K. Wershil, and S. J. Galli. 1994. The *c-kit* ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. *Am. J. Pathol.* 144:321.
19. Huang, E. J., K. H. Nocka, J. Buck, and P. Besmer. 1992. Differential expression of two cell associated forms of the kit-ligand: KL-1 and KL-2. *Mol. Biol. Cell* 3:349.
20. Dastyh, J., and D. D. Metcalf. 1994. Stem cell factor induces mast cell adhesion to fibronectin. *J. Immunol.* 152:213.
21. T. Kinashi, and T. A. Springer. 1994. Steel factor and *c-kit* regulate cell-matrix adhesion. *Blood* 83:1033.
22. Rennick, D., B. Hunte, G. Holland, and L. Thompson-Snipes. 1995. Cofactors are essential for stem cell factor-dependent growth and maturation of mast cell progenitors: comparative effects of interleukin-3 (IL-3), IL-4, IL-10, and fibroblasts. *Blood* 85:57.
23. Levi-Schaffer, F., and N. Riesel. 1989. In vitro regeneration of activated rat peritoneal mast cells cocultured with 3T3 fibroblasts. *Cell. Immunol.* 119:30.
24. Levi-Schaffer, F., R. Kelav-Appelbaum, and E. Rubinchik. 1995. Human foreskin mast cell viability and functional activity is maintained ex vivo by coculture with fibroblasts. *Cell. Immunol.* 162:211.
25. Levi-Schaffer, F., K. F. Austen, P. M. Gravallesse, and R. L. Stevens. 1986. Coculture of interleukin-3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. *Proc. Natl. Acad. Sci. USA* 83:6485.
26. Levi-Schaffer, F., and E. Rubinchik. 1995. Activated mast cells are fibrogenic for 3T3 fibroblasts. *J. Invest. Dermatol.* 104:999.
27. Galli, S. J., K. M. Zsebo, and E. N. Geissler. 1994. The kit ligand, stem cell factor. *Adv. Immunol.* 55:1.
28. Gordon, J. R., and S. J. Galli. 1994. Promotion of mouse fibroblast collagen gene expression by mast cells stimulated via the Fc epsilon RI: role for mast cell-derived transforming growth factor beta and tumor necrosis factor alpha. *J. Exp. Med.* 180:2027-2037.
29. Baggolini, M. 1996. Eotaxin: a VIC (very important chemokine) of allergic inflammation? *J. Clin. Invest.* 97:587.
30. Rothenberg, M. E., R. Ownbey, P. D. Mehlhop, P. M. Loisel, M. van de Rijn, J. V. Bonventre, H. C. Oettgen, P. Leder, and A. D. Luster. 1996. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin-5 in mice. *Mol. Med.* 2:334.
31. Lukacs, N. W., S. L. Kunkel, R. M. Strieter, H. Evanoff, M. L. Key, and D. D. Taub. 1996. The role of stem cell factor (*c-kit* ligand) and inflammatory cytokines in pulmonary mast cell activation. *Blood* 87:2262.
32. Evanoff, H., M. D. Burdick, S. A. Moore, S. L. Kunkel, and R. M. Strieter. 1992. A sensitive ELISA for the detection of human monocyte chemoattractant protein-1 (MCP-1). *Immunol. Invest.* 21:39.
33. Levi-Schaffer, F., E. T. Dayton, K. F. Austen, A. Hein, J. P. Caulfield, P. M. Gravallesse, F. T. Liu, and R. L. Stevens. 1987. Mouse bone marrow-derived mast cells cocultured with fibroblasts: morphology and stimulation-induced release of histamine, leukotriene B4, C4, and prostaglandin D2. *J. Immunol.* 139:3431.
34. Wershil, B. K., M. Tsai, N. Geissler, K. M. Zsebo, and S. J. Galli. 1992. The rat *c-kit* ligand, stem cell factor, induces *c-kit* receptor-dependent mouse mast cell activation in vivo: evidence that signalling through the *c-kit* receptor can induce expression of cellular activation. *J. Exp. Med.* 175:245.
35. Lukacs, N. W., S. L. Kunkel, R. M. Strieter, H. L. Evanoff, R. G. Kunkel, M. L. Key, and D. D. Taub. 1996. The role of stem cell factor (*c-kit* ligand) and inflammatory cytokines in pulmonary mast cell activation. *Blood* 87:2262.
36. Lukacs, N. W., R. M. Strieter, P. M. Lincoln, E. Brownell, D. M. Pullen, H. J. Schock, S. W. Chensue, D. D. Taub, and S. L. Kunkel. 1996. Stem cell factor (*c-kit* ligand) influences eosinophil recruitment in allergic airway inflammation. *J. Immunol.* 156:3945.
37. Donaldson, L. E., E. Schmitt, J. F. Huntley, G. F. Newlands, and R. K. Grencis. 1996. A critical role for stem cell factor and *c-kit* in host protective immunity to an intestinal helminth. *Int. Immunol.* 8:559.
38. Corrigan, C. J., and A. B. Kay. 1992. T cells and eosinophils in the pathogenesis of asthma. *Immunol. Today* 13:501.
39. Noguchi, H., G. M. Kephart, T. V. Colby, and G. J. Gleich. 1992. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. *Am. J. Pathol.* 140:521.
40. Fujimoto, K., K. Kubo, S. Yamaguchi, T. Honda, and Y. Matsuzawa. 1995. Eosinophil activation in patients with pulmonary fibrosis. *Chest* 108:48.
41. Jose, P. J., D. A. Griffiths-Johnson, P. D. Collins, D. T. Walsh, R. Moqbel, N. F. Totty, O. Truong, J. J. Hsuan, and T. J. Williams. 1994. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. *J. Exp. Med.* 179:881.
42. Bartels, J., C. Schluter, E. Richter, N. Noso, R. Kulke, E. Christophers, and J. M. Schroder. 1996. Human dermal fibroblasts express eotaxin: molecular cloning, mRNA expression and identification of eotaxin sequence variants. *Biochem. Biophys. Res. Commun.* 225:1045.
43. Tenschler, K., B. Metzner, E. Schopf, J. Norgauer, and W. Czech. 1996. Recombinant human eotaxin induces oxygen radical production, Ca<sup>2+</sup> mobilization, actin reorganization, and CD11b upregulation in human eosinophils via a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein. *Blood* 88:3195.
44. Gao, J. L., A. I. Sen, M. Kitaura, O. Toshie, M. E. Rothenberg, P. M. Murphy, and A. D. Luster. 1996. Identification of a mouse eosinophil receptor for the CC chemokine eotaxin. *Biochem. Biophys. Res. Commun.* 223:679.
45. Rothenberg, M. E., A. D. Luster, and P. Leder. 1995. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. *Proc. Natl. Acad. Sci. USA* 92:8960.
46. Tsai, M., T. Takeishi, H. Thompson, K. E. Langley, K. M. Zsebo, D. D. Metcalfe, E. N. Geissler, and S. J. Galli. 1991. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat *c-kit* ligand, stem cell factor. *Proc. Natl. Acad. Sci. USA* 88:6382.